
    
      This is a phase II clinical trial of everolimus, an mTOR inhibitor, plus cisplatin
      chemotherapy in patients with triple negative breast cancer (TNBC) who have residual disease
      after completion of neoadjuvant chemotherapy. Everolimus and cisplatin will be administered
      for 12 weeks. Patients will undergo surgery after treatment completion. Patients will have
      breast biopsy prior to receiving the study treatment.
    
  